Pylarify pet radiopharmaceutical
Ended Awarded Last action
- Contract number
- 36C24925N0010
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 9
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,051,561
Award facts
- Contract value 100% obligated
- $1,051,560.54 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Nashville, TN 37212, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$77,969 | |
| Supplemental Agreement for work within scope | $227,349 | |
| Original award | $902,180 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a $1,051,560.54 firm fixed-price blanket purchase agreement call by Veterans Integrated Service Network 9 on November 1, 2024, for the supply of PYLARIFY PET radiopharmaceutical, with a modification to increase quantities. The award, with an ultimate completion date of October 31, 2027, will be performed in Nashville, Tennessee, and carries no set-aside designation. This contract is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a master contract vehicle that enables the Veterans Health Administration to procure critical diagnostic imaging agents efficiently across multiple facilities and service networks.
PYLARIFY (piflufolastat F-18) is a radioactive diagnostic agent used in positron emission tomography scans for the detection and localization of prostate cancer, providing essential diagnostic capabilities for the Veterans Health Administration's oncology imaging programs. This award reflects the Department of Veterans Affairs' continued reliance on Progenics Pharmaceuticals as a primary supplier of radiopharmaceuticals, with the company maintaining an extensive federal contracting portfolio that includes over 150 individual awards from multiple federal healthcare agencies, including several blanket purchase agreements with individual Veterans Integrated Service Networks valued between $793,918 and $9.07 million through 2027 and 2030.
Quick answers
Who was awarded contract 36C24925N0010?
36C24925N0010 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 9 (Veterans Health Administration) on November 1, 2024.
How much is contract 36C24925N0010 worth?
The government has obligated $1,051,561 on 36C24925N0010.
Is contract 36C24925N0010 an order under another contract?
Yes. 36C24925N0010 is a BPA call under 36F79719D0170-36C24923A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24925N0010 competed?
The extent of competition for 36C24925N0010 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award